Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | PEPD | P12955 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3151603 | 1.00 | CYP1A2 (0.38) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL3686565 | 1.00 | CYP1A2 (0.38) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL3152635 | 1.00 | CYP1A2 (0.38) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL13450787 | 1.00 | CYP1A2 (0.38) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL1924296 | 1.00 | CYP1A2 (0.38) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL14547320 | 1.00 | CYP1A2 (0.38) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL7628296 | 1.00 | CYP1A2 (0.38) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL3156153 | 1.00 | CYP1A2 (0.38) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL21622002 | 1.00 | CYP1A2 (0.38) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL121350 | 1.00 | CYP1A2 (0.38) | CYP1A2USP2ALDH1A1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2575798-B1 | GASTRORETENTIVE DOSAGE FORMS OF GABA ANALOGS | RUBICON RES PRIVATE LTD (IN) | 2017-08-09 | — | — | EP | claimed |
| EP-1379494-B1 | FUSED BICYCLIC OR TRICYCLIC AMINO ACIDS | WARNER LAMBERT CO (US) | 2010-03-10 | — | — | EP | claimed |
| US-20040092591-A1 | Therapeutic use of fused bicyclic or tricyclic amino acids | BLAKEMORE DAVID CLIVE (GB) | 2004-05-13 | — | — | US | claimed |
| US-6596900-B2 | Brain, nervous system, neurodegenerative, gastrointestinal, sleep, rheumatic, and psychological disorders; analgesics, antiepileptic agents | PFIZER INC | 2003-07-22 | — | — | US | claimed |
| US-20030078300-A1 | Fused bicyclic or tricyclic amino acids | PFIZER INC. | 2003-04-24 | — | — | US | claimed |
| EP-2575798-B1 | GASTRORETENTIVE DOSAGE FORMS OF GABA ANALOGS | RUBICON RES PRIVATE LTD (IN) | 2017-08-09 | — | — | EP | disclosed |
| WO-2017114225-A1 | FUSED TRICYCLIC Γ-AMINO ACID DERIVATIVE AND PREPARATION METHOD AND PHARMACEUTICAL APPLICATION THEREOF | 四川海思科制药有限公司 | 2017-07-06 | — | — | WO | disclosed |
| WO-2017107907-A1 | CONDENSED RING Γ-AMINO ACID DERIVATIVE AND PREPARATION METHOD AND MEDICAL USE THEREOF | 四川海思科制药有限公司 | 2017-06-29 | — | — | WO | disclosed |
| US-20140206670-A1 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS | PFIZER INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-20130078290-A1 | Gastroretentive Dosage Forms Of GABA Analogs | RUBICON RESEARCH PRIVATE LIMITED (IN) | 2013-03-28 | — | — | US | disclosed |
| US-20120329781-A1 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS | PFIZER INC | 2012-12-27 | — | — | US | disclosed |
| US-20110294881-A1 | METHODS FOR TREATING LOWER URINARY TRACT DISORDERS USING alpha2delta SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS | EDUSA PHARMACEUTICALS, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| US-20040072904-A1 | Liquid pharmaceutical compositions | VIATRIS SPECIALTY LLC. | 2004-04-15 | — | — | US | disclosed |
| EP-1395242-A1 | LIQUID PHARMACEUTICAL COMPOSITION | Warner-Lambert Company LLC (US) | 2004-03-10 | — | — | EP | disclosed |
| WO-2004016259-A1 | SYNERGISTIC COMBINATION OF AN ALPHA-2-DELTA LIGAND AND A PDEV INHIBITOR FOR USE IN THE TREATMENT OF PAIN | PFIZER LIMITED (GB) | 2004-02-26 | — | — | WO | disclosed |
| WO-2003070237-A1 | COMBINATIONS OF AN ALPHA-2-DELTA LIGAND WITH A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 | WARNER-LAMBERT COMPANY LLC (US) | 2003-08-28 | — | — | WO | disclosed |
| US-6596900-B2 | Brain, nervous system, neurodegenerative, gastrointestinal, sleep, rheumatic, and psychological disorders; analgesics, antiepileptic agents | PFIZER INC | 2003-07-22 | — | — | US | disclosed |
| US-20030078300-A1 | Fused bicyclic or tricyclic amino acids | PFIZER INC. | 2003-04-24 | — | — | US | disclosed |
| US-20020198261-A1 | Liquid pharmaceutical compositions | KULKARNI NEEMA M (US) | 2002-12-26 | — | — | US | disclosed |
| WO-2002094220-A1 | LIQUID PHARMACEUTICAL COMPOSITION | WARNER-LAMBERT COMPANY LLC (US) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078300-A1 | Fused bicyclic or tricyclic amino acids | AADAT, SLC1A2, BCAT1 | CYP1A2 966/4885USP2 4035/4885ALDH1A1 1302/4885 |
| US-20020198261-A1 | Liquid pharmaceutical compositions | GABRB2, GABRB1, GABRA6 | CYP1A2 1219/4885USP2 3682/4885ALDH1A1 932/4885 |
| US-20040072904-A1 | Liquid pharmaceutical compositions | GABRB2, GABRB1, GABRA6 | CYP1A2 1219/4885USP2 3682/4885ALDH1A1 932/4885 |
| US-20040092591-A1 | Therapeutic use of fused bicyclic or tricyclic amino acids | BCAT1, BCAT2, AADAT | CYP1A2 2278/4885USP2 3447/4885ALDH1A1 3565/4885 |
| US-20120329781-A1 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS | SLC6A2, OPRD1, ADRB2 | CYP1A2 1017/4885USP2 4154/4885ALDH1A1 1636/4885 |
| US-20140206670-A1 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS | SLC6A2, OPRD1, ADRB2 | CYP1A2 1017/4885USP2 4154/4885ALDH1A1 1636/4885 |
| US-20110294881-A1 | METHODS FOR TREATING LOWER URINARY TRACT DISORDERS USING alpha2delta SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS | GABRB2, GABRB3, GABRB1 | CYP1A2 1185/4885USP2 1632/4885ALDH1A1 1342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.